After maintaining a neutral to negative stance for four years, we upgrade GSKCH to BUY with TP of Rs 5,950 (earlier Rs5,300) based on fwd. P/E of 29x.Strong pricing power, category leadership and attractive valuation (26x P/E for FY19E) is a reality and improvement in the core category volume growth